Search Results
Exploiting Novel Therapeutic Vulnerabilities in Chronic Myelomonocytic Leukemia
The overall objective of this project is to identify novel pathways that may be targeted for therapeutic benefit in CMML. We have identified abnormal inflammation mediated by RSK1 in CMML patient cells, and we hypothesize that RSK1 drives CMML disease development. We thus propose studies to determine how RSK1 contributes to CMML pathogenesis, and to evaluate the therapeutic potential of RSK1 inhibition for CMML patients.
BURLINGTON STORES RAISES RECORD-BREAKING $5.1 MILLION FOR LLS
Burlington Stores and The Leukemia & Lymphoma Society (LLS) joined forces for the 17th consecutive year to help save lives and bring smiles to those touched by blood cancer. From September 9 through December 1, Burlington’s more than 670 locations nationwide encouraged customers to donate $1 or more at checkout to support LLS’s goal to create a world without blood cancer. This campaign, combined with Burlington’s corporate associate fundraising efforts, raised a record smashing $5.1 million for LLS, helping the organization fund lifesaving research and treatments.
Doxorubicin
Doxorubicin is FDA approved to treat people who have some kinds of blood cancer, including acute lymphoblastic leukemia, acute myeloblastic leukemia, and Hodgkin and non-Hodgkin lymphoma.
Topotecan
Topotecan is an FDA-approved cancer drug that is used to treat people who have certain types of cancer including acute myeloid leukemia and acute lymphoblastic leukemia. This drug may cause a temporary loss of hair in some people. After treatment with topotecan has ended, normal hair growth should return.
EXPANDING FEDERAL RESOURCES FOR BLOOD CANCER RESEARCH
Learn how The Leukemia & Lymphoma Society (LLS) played a key role in restoring research for all blood cancers as a priority funding area for 2018.
When we think of the federal government’s investments in medical research, we almost always think of the National Institutes of Health (NIH), our nation’s medical research agency. For more than a century, NIH has paved the way for scientific breakthroughs that are helping people live longer, healthier lives.
Reflections from the #ASH19 Meeting
As the 61st Annual ASH (American Society of Hematology) Meeting and Exhibition winds down here in Orlando, here are some thoughts on where things stand in the world of blood cancers.
A phase 1b/2 study targeting apoptotic and signaling pathways in T-acute lymphoblastic leukemia
T-acute lymphoblastic leukemia (T-ALL) is an aggressive leukemia with limited treatment options after first-line chemotherapy. Our preclinical work in animal models of T-ALL demonstrated the activity of a novel-novel combination treatment strategy, which includes LP-118 (activator of suicide pathways within leukemic cells) and tyrosine kinase inhibitors (inhibiting growth-promoting LCK and ACK1 signaling pathways).
Understanding Mutations to Treat MDS
Benjamin Ebert is researching what genetic mutations cause myelodysplastic syndromes (MDS), a group of disorders in which the bone marrow fails to produce sufficient blood cells, and how that information can be used to determine prognosis and therapy. MDS frequently progresses to an acute leukemia.
Blood Cancer Discovery Helping Cardiovascular Patients
An exciting scientific discovery, originally found through blood cancer research, makes headlines when researchers uncover new implications for cardiovascular disease.
The Leukemia & Lymphoma Society (LLS) is laser-focused on finding cures for patients with blood cancers. But did you know that the research we support has far greater reach? In fact, many of the therapeutic advances that occurred first in blood cancer are now helping patients with other types of cancers and serious diseases.
Rituximab
is FDA approved for the treatment of:
A Cancer Survivor Gives Back
When I meet newly diagnosed cancer patients and their caregivers, a familiar look greets me. I have seen this look countless times. In waiting rooms, during a weekly support lunch for patients and caregivers, and on my own mother’s face.
It is a look of fear, confusion and doubt. It is a look that expresses the need for survival at all costs, yet without any assurance of success. It is a look that I can still see when I look in the mirror.
That look is often replaced almost immediately after I say: “Hi, my name is Ron. I am a leukemia and stem-cell transplant survivor.”
Clinical Trials: Why They Matter and How to Make Them More Accessible
Cancer treatments can be lifesaving. As an organization, The Leukemia & Lymphoma Society (LLS) has invested more than $1.7 billion in blood cancer research since its inception in 1949—all with the hope that this research leads to scientific breakthroughs that improve and save lives.
But to make sure this research leads to safe and innovative treatments, we have to thoroughly test it.
A Source of Hope: Understanding Bone Marrow and Stem Cell Transplants
Imagine a community filled with families, friends, and healthcare professionals united to transform the meaning of living with blood cancer. This diverse group of people—including researchers, doctors, care partners, and healthcare teams—are bound together by hope, resilience, and a shared goal: to overcome the challenges and live longer better lives.
Ibrutinib
Ibrutinib has been FDA-approved to treat:
- Patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (SLL) with 17p deletion.
- Patients with Waldenström macroglobulinemia (WM).
- Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
Interferon alfa-2a
Interferons are substances naturally produced by cells in the body to help fight infections and tumors. They may also be synthetic versions of these substances. Interferon alfa-2a is FDA approved to treat people who have hairy cell leukemia and Philadelphia chromosome positive chronic myeloid leukemia who are minimally pretreated (within 1 year of diagnosis). It may cause a temporary loss of hair. After treatment has ended, normal hair growth should return.